OKOrhun H. Kantarci

Orhun H. Kantarci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Orhun H. Kantarci has a total of 232 co-authors. Here are the top co-authors by number of shared publications:

  • Burcu Zeydan

    Department of Neurology, Mayo Clinic, Rochester, MN, USA

    16 shared publications
  • Aksel Siva

    Cerrahpasa School of Medicine, Istanbul University, Turkey

    14 shared publications
  • Istvan Pirko

    From the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology (M.N., M.M.P.S., B.M.K., I.P., S.J.P., C.F.L., J.H.N., B.G.W., M.R., O.H.K.), Department of Neurology, and Division of Biomedical Statistics & Informatics (D.J.C., E.J.A.), Mayo Clinic College of Medicine, Rochester, MN; International Clinical Research Center (M.N.), St. Anne's University Hospital Brno, Brno, Czech Republic; Department of Neurology (N.A.Z.), Wake Forest Medical Center, Winston-Salem, NC; Department of...

    11 shared publications
  • Moses Rodriguez

    Mayo Clinic, Rochester, MN

    11 shared publications
  • Darin T. Okuda

    The University of Texas Southwestern Medical Center, Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, Dallas, TX, USA; The University of Texas Southwestern Medical Center, Peter O'Donnell Jr. Brain Institute, Dallas, TX, USA

    7 shared publications
  • Kejal Kantarci

    Department of Radiology, Mayo Clinic , Rochester, MN 55905

    6 shared publications

Latest Publications

  • Corrigendum to “A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome” [Multiple Sclerosis and Related Disorders 112 (2026) 107312]

    by Albert Aboseif, Nur Neyal, B. Mark Keegan, Jeanette E. Eckel-Passow, Aksel Siva, Christine Lebrun-Frenay, Darin T. Okuda, W. Oliver Tobin, Burcu Zeydan, Orhun H. Kantarci

  • A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome

    by Albert Aboseif, Nur Neyal, B. Mark Keegan, Jeanette E. Eckel-Passow, Aksel Siva, Christine Lebrun-Frenay, Darin T. Okuda, W. Oliver Tobin, Burcu Zeydan, Orhun H. Kantarci

  • Open Access

    Subclinical Optic Nerve Involvement in Radiologically Isolated Syndrome: Multimodal Detection and Diagnostic Impact

    by Christine Lebrun‐Frenay, Cassandre Landes‐Château, Lydiane Mondot, Mikael Cohen, Margherita Popolo, Jérôme de Seze, Bertrand Bourre, Françoise Durand‐Dubief, Olivier Casez, Orhun H. Kantarci, et al.

    Objectives: We aimed to determine the frequency of subclinical optic nerve (ON) lesions using MRI, optical coherence tomography (OCT), and visual evoked potentials (VEP) in radiologically isolated syndrome (RIS), and to assess their diagnostic and prognostic significance. Methods: We conducted a retrospective, multicenter study of 179 RIS individuals followed in clinical practice who met the 2023 RISC criteria. The diagnostic performance of the 2024 McDonald criteria, with and without optic nerve assessment, was evaluated and compared with that of the 2017 criteria. Associations with clinical conversion, comorbidities, and MRI disease activity were analyzed using multivariate models. Results: Silent ON lesions appeared in 107/179 (59.8%) individuals, mainly detected by VEP (100/164; 61.0%) and OCT (69/118; 58.5%), with routine MRI identifying 31/166 (18.7%). During follow‐up, 71 (39.7%) had a first clinical event. The presence, laterality, or number of silent ON lesions did not correlate with clinical conversion, event type, or MRI activity. Younger age and the absence of comorbidities associated with other MRI lesions, rather than with ON lesions, were associated with clinical conversion. Including ON in the 2024 McDonald criteria increased sensitivity but decreased specificity, with 17/179 (9.5%) meeting dissemination‐in‐space criteria solely due to ON lesions. Interpretation: Subclinical ON lesions are common in RIS and are mainly found by OCT and VEP, not routine MRI. Including ON increases sensitivity but does not predict clinical conversion and may lower specificity. These findings suggest cautious interpretation of ON and support a multimodal assessment approach in RIS.


  • Open Access

    Decoding Thalamic Glial Interplay in Multiple Sclerosis Through Proton Magnetic Resonance Spectroscopy and Positron Emission Tomography

    by Firat Kara, Nur Neyal, Michael G. Kamykowski, Christopher G. Schwarz, June Kendall-Thomas, Holly A. Morrison, Matthew L. Senjem, Scott A. Przybelski, Angela J. Fought, John D. Port, et al.

    The study assesses the relationship between thalamic proton-MR spectroscopy (1H-MRS) metabolites and thalamic 11C-ER176 translocator-protein positron emission tomography (TSPO-PET) standardized uptake value ratios (SUVR) to advance our understanding of thalamic involvement in multiple sclerosis (MS)-associated neurodegeneration and disability. In this prospective cross-sectional study, patients with MS (pwMS) and controls underwent 3T-MRI, 1H-MRS, and 11C-ER176-PET targeting the thalamus. MRI-derived thalamic volume was normalized by intracranial volume. 1H-MRS metabolites—N-acetylaspartate (NAA), glutamate (Glu), glutamine (Gln), total choline (tCho), and myo-inositol (mIns)—were normalized to total creatine (tCr). Clinical disability was evaluated using MS-specific tests of Expanded Disability Status Scale-EDSS and MS-functional composite-MSFC (including Paced Auditory Serial Addition Test-PASAT). Compared to controls (n = 30), pwMS (n = 21) exhibited smaller thalamic volume, higher thalamic 1H-MRS mIns/tCr (putative gliosis marker), and higher thalamic 11C-ER176-PET SUVR (glial density marker). In pwMS, higher thalamic mIns/tCr (r = −0.67) and tCho/tCr (r = −0.52) correlated with smaller thalamic volume. In pwMS, higher thalamic mIns/tCr correlated with higher thalamic 11C-ER176-PET SUVR (r = 0.48) and decreased cognitive function (PASAT, rho = −0.48). In controls, decreased thalamic NAA/tCr correlated with increased thalamic 11C-ER176-PET SUVR (r = −0.41). Thalamus, a core central nervous system relay, is affected early in MS disease course. Glial-mediated innate immune activation in the thalamus, evaluated by increased 1H-MRS mIns/tCr and 11C-ER176-PET SUVR, is associated with loss of thalamic volume and increased disability in pwMS. The multimodal imaging approach with 1H-MRS mIns/tCr and 11C-ER176-PET SUVR emerges as potential glial biomarkers, to better understand disease mechanisms and evaluate therapeutic interventions targeting glial activity in MS.


  • From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis

    by Nur Neyal, Katelynn J. Krey, Holly A. Morrison, Nabeela Nathoo, Elizabeth J. Atkinson, Jiye Son, Eoin P. Flanagan, Sean J. Pittock, Ugur Uygunoglu, Orhun H. Kantarci, et al.

    Background Patient-reported outcome measures (PROMs) improve multiple sclerosis (MS) management by reflecting patients’ perspectives of their disease. Mayo Clinic Electronic Emoji Based Neurological Impairment Status (MEBNIS) is a short PROM consisting of four equally-weighted domains (MemoryMEBNIS, MoodMEBNIS, Fatigue-SleepinessMEBNIS, and AmbulationMEBNIS) and CompositeMEBNIS, which are based on emojis. Objective To investigate the correlations of MEBNIS with patient-reported, examination-based, performance-based, and radiological metrics of disease severity in persons with MS (pwMS). Methods PwMS (n = 195) prospectively completed MEBNIS, Expanded Disability Status Scale (EDSS), MS Functional Composite (MSFC) and its subtests [25-Foot Walk Test (25FWT), 9-Hole Peg Test (9HPT), Paced Auditory Serial Addition Test (PASAT)], Beck Depression Inventory (BDI), Fatigue Questionnaire (FQ), and Epworth Sleepiness Scale (ESS) between May 2021 and May 2024. Participants also underwent brain MRIs. Correlations were summarized using Spearman’s rank correlation coefficients. Results MemoryMEBNIS correlated (p≤0.001) with PASAT (rho = −0.25), ESS (rho = 0.24), FQ (rho = 0.36), and BDI (rho = 0.36). MoodMEBNIS correlated (prho = 0.40) and BDI (rho = 0.46). Fatigue-SleepinessMEBNIS correlated (prho = 0.49), FQ (rho = 0.59), and BDI (rho = 0.44). AmbulationMEBNIS correlated (prho = 0.69), MSFC z-score (rho = −0.59), 25FWT (rho = 0.66), 9HPT (rho = 0.54), PASAT (rho = −0.32), FQ (rho = 0.41), and BDI (rho = 0.37). CompositeMEBNIS correlated (prho = 0.47), MSFC z-score (rho = −0.42), 25FWT (rho = 0.49), 9HPT (rho = 0.36), PASAT (rho = −0.26), ESS (rho = 0.38), FQ (rho = 0.64), and BDI (rho = 0.58). MemoryMEBNIS, AmbulationMEBNIS and CompositeMEBNIS correlated with cortical gray matter (MemoryMEBNIS rho = −0.17; AmbulationMEBNIS rho = −0.30; CompositeMEBNIS rho = −0.20) and thalamus (MemoryMEBNIS rho = −0.17; AmbulationMEBNIS rho = −0.20; CompositeMEBNIS rho = −0.17) volumes (p<0.05). Conclusions As a novel visual PROM, MEBNIS correlates with established patient-reported, examination-based, performance-based, and radiological metrics of MS severity. It offers a fast, intuitive, and accessible multi-domain evaluation of impairment and disease severity in MS, applicable to both clinical practice and clinical trials as a potential digital tool.


  • Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations

    by Le H. Hua, Andrew J. Solomon, Silvia Tenembaum, Antonio Scalfari, Àlex Rovira, Kevin Rostasy, Scott D. Newsome, Ruth Ann Marrie, Melinda Magyari, Orhun Kantarci, et al.

    Importance: While the typical onset of multiple sclerosis (MS) occurs in early adulthood, 2% to 10% of cases initially present prior to age 18 years, and approximately 5% after age 50 years. Guidance on approaches to differential diagnosis in suspected MS specific to these 2 age groups is needed.Observations: There are unique biological factors in children younger than 18 years and in adults older than age 50 years compared to typical adult-onset MS. These biological differences, particularly immunological and hormonal, may influence the clinical presentation of MS, resilience to neuronal injury, and differential diagnosis. While mimics of MS at the typical age at onset have been described, a comprehensive approach focused on the younger and older ends of the age spectrum has not been previously published.Conclusions and Relevance: An international committee of MS experts in pediatric and adult MS was formed to provide consensus guidance on diagnostic approaches and key clinical and paraclinical red flags for non-MS diagnosis in children and older adults.


  • Multiple sclerosis in Somali Americans: Nature or nurture?

    by Nabeela Nathoo, Nur Neyal, Elizabeth J. Atkinson, Brian G. Weinshenker, Jan-Mendelt Tillema, B.mArk Keegan, Sean J. Pittock, W.oLiver Tobin, Eoin P. Flanagan, Ralitza Gavrilova, et al.


  • MR Imaging Features of Critical Spinal Demyelinating Lesions Associated with Progressive Motor Impairment

    by B. Mark Keegan, Steven A. Messina, Dennis Hanson, David Holmes, Jon Camp, Elia Sechi, Shreya Nayak, Benan Barakat, Rowaid Ahmad, Jay Mandrekar, et al.

    BACKGROUND AND PURPOSE: Progressive MS is typically heralded by a myelopathic pattern of asymmetric progressive motor weakness. Focal individual “critical” demyelinating spinal cord lesions anatomically associated with progressive motor impairment may be a compelling explanation for this clinical presentation as described in progressive solitary sclerosis (single CNS demyelinating lesion), progressive demyelination with highly restricted MR imaging lesion burden (2–5 total CNS demyelinating lesions; progressive paucisclerotic MS), and progressive, exclusively unilateral hemi- or monoparetic MS (>5 CNS demyelinating progressive unilateral hemi- or monoparetic MS [PUHMS] lesions). Critical demyelinating lesions appear strikingly similar across these cohorts, and we describe their specific spinal cord MR imaging characteristics. MATERIALS AND METHODS: We performed a retrospective, observational MR imaging study comparing spinal cord critical demyelinating lesions anatomically associated with progressive motor impairment with any additional “noncritical” (not anatomically associated with progressive motor impairment) spinal cord demyelinating lesions. All spinal cord MR images (302 cervical and 91 thoracic) were reviewed by an experienced neuroradiologist with final radiologic assessment on the most recent MR imaging. Anatomic association with clinical progressive motor impairment was confirmed independently by MS subspecialists. RESULTS: Ninety-one individuals (PUHMS, 37 [41%], progressive paucisclerosis 35 [38%], progressive solitary sclerosis 19 [21%]) with 91 critical and 98 noncritical spinal cord MR imaging demyelinating lesions were evaluated. MR imaging characteristics that favored critical spinal cord demyelinating lesions over noncritical lesions included moderate-to-severe, focal, lesion-associated spinal cord atrophy: 41/91 (45%) versus 0/98 (0%) (OR, 161.91; 9.43 to >999.9); lateral column axial location (OR, 10.43; 3.88–28.07); central region (OR, 3.23; 1.78–5.88); ventral column (OR, 2.98; 1.55–5.72); and larger lesion size of the axial width (OR, 2.01;1.49–2.72), transverse axial size (OR, 1.66; 1.36–2.01), or lesion area (OR, 1.14; 1.08–1.2). Multiple regression analysis revealed focal atrophy and lateral axial location as having the strongest association with critical demyelinating lesions. CONCLUSIONS: Focal, lesion-associated atrophy, lateral column axial location, and larger lesion size are spinal cord MR imaging characteristics of critical demyelinating lesions. The presence of critical demyelinating lesions should be sought as these features may be associated with the development of progressive motor impairment in MS.


  • Open Access

    The diagnostic value of the central vein sign in radiologically isolated syndrome

    by Cassandre Landes‐Chateau, Michael Levraut, Darin T. Okuda, Albert Themelin, Mikael Cohen, Orhun H. Kantarci, Aksel Siva, Daniel Pelletier, Lydiane Mondot, Christine Lebrun‐Frenay, et al.

    Objective: The radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS). Increasing evidence suggests that the central vein sign (CVS) enhances lesion specificity, allowing for greater MS diagnostic accuracy. This study evaluated the diagnostic performance of the CVS in RIS.Methods: Patients were prospectively recruited in a single tertiary center for MS care. Participants with RIS were included and compared to a control group of sex and age‐matched subjects. All participants underwent 3 Tesla magnetic resonance imaging, including postcontrast susceptibility‐based sequences, and the presence of CVS was analyzed. Sensitivity and specificity were assessed for different CVS lesion criteria, defined by proportions of lesions positive for CVS (CVS+) or by the absolute number of CVS+ lesions.Results: 180 participants (45 RIS, 45 MS, 90 non‐MS) were included, representing 5285 white matter lesions. Among them, 4608 were eligible for the CVS assessment (970 in RIS, 1378 in MS, and 2260 in non‐MS). According to independent ROC comparisons, the proportion of CVS+ lesions performed similarly in diagnosing RIS from non‐MS than MS from non‐MS (p = 0.837). When a 6‐lesion CVS+ threshold was applied, RIS lesions could be diagnosed with an accuracy of 87%. MS could be diagnosed with a sensitivity of 98% and a specificity of 83%. Adding OCBs or Kappa index to CVS biomarker increased the specificity to 100% for RIS diagnosis.Interpretation: This study shows evidence that CVS is an effective imaging biomarker in differentiating RIS from non‐MS, with similar performances to those in MS.